Non-Invasive Glucose Monitoring Devices Market By Product Type (Wearable Continuous Monitoring Devices, Handheld/Portable Spot-Reading Devices, Patch-Based Transdermal Monitoring Devices, Tabletop/Professional Monitoring Systems); By Technology (Optical Spectroscopy, Raman Spectroscopy, Mid-Infrared Photothermal Detection, Radiofrequency and Microwave Sensing, Reverse Iontophoresis/Transdermal Extraction, Other Emerging Technologies); By Application (Type 2 Diabetes Monitoring, Type 1 Diabetes Monitoring, Prediabetes and Metabolic Health Monitoring, Gestational Diabetes Monitoring, General Wellness and Nutrition Monitoring); By End User (Homecare Users, Hospitals and Diabetes Clinics, Diagnostic and Research Centers, Wellness and Weight-Management Programs); By Geography, Segment Revenue Estimation and Forecast, 2026–2032

Non-Invasive Glucose Monitoring Devices Market: Clinical Validation Begins Converting a Research Category into a Commercial Market

The Global Non-Invasive Glucose Monitoring Devices Market is valued at USD 41.2 million in 2025 and is projected to reach USD 202.0 million by 2032, expanding at a CAGR of 25.5%, according to Strategic Market Research.

 

The non-invasive glucose monitoring market is characterized by a small group of technology developers pursuing distinct sensing approaches, including mid-infrared photothermal detection, radiofrequency and microwave sensing, Raman spectroscopy, and reverse iontophoresis. Key innovators include DiaMonTech, Afon Technology, RSP Systems, HAGAR, Nemaura Medical, and Know Labs. Despite continued product development, regulatory progress, and growing interest in needle-free glucose monitoring, none of these companies has achieved commercialization at a scale comparable with established conventional continuous glucose monitoring manufacturers.

 

DiaMonTech is developing D-Pocket, a handheld mid-infrared photothermal glucose monitor, and D-Sensor, a miniaturized platform intended for future wearable integration. Afon Technology is advancing Glucowear, a wrist-worn device that uses radiofrequency and microwave sensing for continuous glucose monitoring. RSP Systems is developing GlucoBeam Smart, a Raman spectroscopy-based optical device primarily intended for prediabetes and type 2 diabetes monitoring. HAGAR is building GWave, a radiofrequency wrist-worn monitoring platform that has received FDA Breakthrough Device Designation. Nemaura Medical introduced sugarBEAT, a reverse-iontophoresis patch-based glucose monitoring system, together with the proBEAT wellness platform and the Miboko AI-enabled metabolic health application. Know Labs developed the KnowU prototype using its Bio-RFID sensing technology before divesting its sensor business.

 

Diabetes Burden Creates Demand, but Accuracy Determines Commercial Eligibility

The International Diabetes Federation estimates that 588.7 million adults aged 20–79 were living with diabetes in 2024, including 251.7 million who were undiagnosed. Approximately 3.44 million deaths were attributable to diabetes, while global diabetes-related health expenditure exceeded USD 1 trillion. Around 81% of adults with diabetes live in low- and middle-income countries, where recurring test-strip and sensor costs can limit access.

CDC estimates that 40.1 million people in the United States had diagnosed or undiagnosed diabetes in 2023. The total included 29.1 million diagnosed patients and 11 million undiagnosed adults. Another 115.2 million adults had prediabetes, while 2.1 million people had diagnosed type 1 diabetes.

These populations support a large monitoring need but do not convert directly into device sales. Insulin-treated patients require readings dependable enough for treatment decisions, while people with prediabetes or general metabolic interests may accept lower-risk wellness feedback. The first commercial products may therefore enter through non-insulin-treated type 2 diabetes, nutrition, weight management, and preventive-health programs before expanding into insulin-dosing applications.

FDA stated in 2024 that it had not authorized, cleared, or approved any smartwatch or smart ring that independently measures or estimates glucose without piercing the skin. Inaccurate readings can cause incorrect insulin or sulfonylurea dosing, making regulatory-grade accuracy the main commercial barrier for medical wearables.

 

DiaMonTech Builds D-Pocket Around Mid-Infrared Photothermal Detection

Product Development and Planned Launch

Berlin-based DiaMonTech is developing the portable D-Pocket and the smaller D-Sensor for future wearable integration. D-Pocket applies mid-infrared photothermal detection: infrared light is absorbed by glucose molecules in the skin, creating a small thermal response that the device measures. The company previously developed the larger D-Base platform for professional settings.

D-Pocket remains under development, and DiaMonTech has not published a commercial availability date. The company expects to begin in European and U.S. markets after completing product development, clinical studies, and certification. D-Sensor is a miniaturized extension of the same technology and is also not available for purchase.

 

Clinical and Financing Progress

DiaMonTech reported that recent testing produced mean absolute relative difference values of 20.7% and 19.6% in real-life comparative conditions. These figures remain above the accuracy achieved by current leading inserted CGMs, but they indicate progress toward a usable external optical system.

In September 2025, the company announced a EUR 12 million financing round to advance D-Pocket, conduct further clinical trials, and prepare international expansion. DiaMonTech stated that more than EUR 35 million had been invested in the business, that it had filed over 100 patents with more than 40 granted, and that distributor letters of intent covered potential pre-orders for 100,000 devices. These commitments indicate channel interest but are not completed product sales.

DiaMonTech’s competitive strength is its accumulated optical intellectual property and progress toward a reusable handheld product. Its main challenge is reducing the equipment into a commercially practical form while improving accuracy and completing regulatory studies.

 

Afon Technology Advances Glucowear as a Wrist-Worn RF Monitor

Product Design and Clinical Program

Afon Technology is developing Glucowear, a wrist-worn device that uses low-power radiofrequency and microwave signals to detect glucose-related changes. The sensor is intended to sit beneath a watch or wearable band and transmit readings to a smartphone application without disposable patches or inserted filaments.

The company has conducted clinical work at the Royal Liverpool Hospital, Swansea Bay University Health Board, Profil, and through an ongoing NHS program. Trials were reported at Profil in July 2020 and November 2024, while a Swansea Bay study was completed in May 2023. Afon’s website continues to describe Glucowear as being in clinical development rather than as a commercially launched product.

 

Funding and 2026 Real-World Test

Afon received a EUR 2.5 million European Innovation Council grant in December 2022 to support development and scale-up. The company had previously indicated an anticipated 2026 launch, but no completed regulatory authorization or broad commercial release had been announced by July 2026.

In March 2026, Afon reported that Glucowear achieved approximately 75% overall accuracy in distinguishing normal from elevated glucose during an initial real-world test. The test demonstrated classification capability rather than precise glucose measurement suitable for treatment decisions. Afon continues to refine its algorithms and sensor reliability.

Afon’s opportunity comes from combining continuous data with a familiar wrist-worn form factor. Its commercial position will depend on whether the company can progress from broad glucose classification to reproducible numerical readings across a larger and more diverse patient population.

 

RSP Systems Positions GlucoBeam Smart for Prediabetes and Type 2 Diabetes

Raman Spectroscopy Platform

Denmark-based RSP Systems is developing GlucoBeam Smart, a non-invasive optical system based on Raman spectroscopy. The device directs light into the skin and analyzes the returned molecular signal to estimate glucose. RSP is currently positioning GlucoBeam primarily around glycemic awareness, prediabetes, and early type 2 diabetes rather than immediate insulin-dosing decisions.

GlucoBeam Smart remains investigational and is not approved for commercial use in the United States or other jurisdictions. The preventive positioning could provide RSP with a lower-risk initial market than type 1 diabetes, while still allowing the company to build data, user experience, and clinical relationships.

 

HAGAR Develops GWave Around Radiofrequency Blood Sensing

GWave Platform and Discovery

Israel-based HAGAR is developing GWave, a radiofrequency system intended to measure glucose continuously through the wrist. The original concept emerged when co-founder Gerry Vaintrub observed that sugar altered the response of an RF research system. HAGAR subsequently developed the discovery into a glucose-sensing prototype connected to a mobile application and cloud platform.

The company’s current product concept uses an RF sensor, proprietary signal-processing algorithms, Bluetooth connectivity, alerts, and cloud-based data sharing. HAGAR intends to reduce the sensor into a smartwatch-compatible format.

 

Regulatory and Clinical Position

GWave received FDA Breakthrough Device Designation, which provides closer interaction with the regulator but does not constitute clearance or approval. HAGAR has reported more than USD 25 million in total funding, including a USD 5 million Series C round and an earlier USD 11.7 million Series B.

A company-reported study using second-generation chips tested participants on two GWave devices against capillary glucose references. Readings between 70 and 140 mg/dL fell within Zone A of the Clarke Error Grid, and HAGAR announced plans for additional studies in Israel and the United States. The company also reported a manufacturing relationship with a Taiwanese RF chip producer to improve reproducibility and support eventual miniaturization.

Peer-reviewed research published in 2024 concluded that real-time non-invasive measurement was technically possible with the GWave platform while calling for larger studies across wider glucose ranges.

 

Nemaura Medical Provides the Main Historical Commercialization Case

sugarBEAT, proBEAT, and Miboko

Nemaura Medical developed sugarBEAT, a reverse-iontophoresis patch that draws glucose through intact skin into a disposable sensor. The patch connects to a rechargeable transmitter and application. Its needle-free design gave Nemaura one of the category’s earliest regulatory and commercial positions, although its extraction method places it outside the strictest definition of fully external sensing.

The company also developed proBEAT as a general-wellness program and launched a beta trial of Miboko, combining glucose information with an artificial-intelligence application focused on food and lifestyle responses.

Historical commercial signals included a provisional Middle East order for 17,500 devices and 1.7 million sensors and a U.S. HealthFleet order for 75,000 proBEAT sensors valued at USD 500,000. These orders demonstrated potential demand for disposable needle-free sensors but did not establish sustained global commercialization.

 

Know Labs Exits Direct Development After Building Bio-RFID Evidence

KnowU and Bio-RFID

Know Labs developed Bio-RFID, a radiofrequency spectroscopy platform intended to identify and quantify glucose without entering the skin. The company built the KnowU prototype as a portable monitoring device and previously considered a wearable UBand format.

Know Labs reported internal studies with MARD results of 12.9% and later 11.3%, although Dexcom G6 readings were used as a reference proxy in parts of the development program. Another study reported 93.37% accuracy in classifying glycemic status as hypoglycemic, normal, or hyperglycemic.

 

Divestiture Changes the Competitive Structure

Know Labs changed its name to USBC and redirected its main business toward financial technology. On April 2, 2026, USBC announced that it had completed the divestiture of its legacy sensor business effective March 27, 2026.

The sensor assets moved to a newly formed entity controlled by former chairman and chief executive Ron Erickson. USBC retained a revenue-sharing interest and provided access to a short-term bridge facility of up to USD 450,000.

The divestiture removes USBC as a direct medical-device developer while allowing the underlying technology to continue under separate ownership. It also illustrates the capital intensity and long development periods associated with non-invasive sensing.

 

Established CGM Companies Set the Commercial Benchmark

Abbott, Dexcom, Medtronic, and Senseonics are not core manufacturers under the strict market definition because their sensors enter or sit beneath the skin. They remain the most important competitive benchmark because they already offer regulated products, clinical evidence, manufacturing capacity, payer coverage, smartphone integration, and recurring sensor revenue.

Non-invasive developers must compete against increasingly convenient and consumer-accessible inserted CGMs rather than against finger-stick meters alone. Their commercial advantage must therefore come from lower long-term cost, reduced skin burden, reusable hardware, easier adoption, or access to populations that do not currently use CGM.

 

Market Outlook

The revised USD 202.0 million forecast for 2032 assumes that the market remains small through the near term and then expands as two or more developers progress into limited commercial availability. DiaMonTech’s financing, RSP’s peer-reviewed evidence, Afon’s ongoing trials, and HAGAR’s regulatory engagement support continued technical progress. Nemaura’s financial difficulties and the Know Labs divestiture show why the forecast should remain far below multibillion-dollar estimates.

Initial revenue is expected to come from research devices, institutional pilots, wellness programs, limited regional sales, technology licensing, and early reusable readers. Larger medical-device revenue will depend on multicenter clinical validation, manufacturing consistency, regulatory authorization, and evidence that the devices can produce dependable readings during normal daily activity.

The first successful product may not immediately replace inserted CGM for insulin dosing. A more probable commercial path begins with prediabetes, non-insulin-treated type 2 diabetes, metabolic-health programs, and intermittent spot monitoring. Companies can then move toward higher-value continuous and treatment-guiding applications as clinical evidence improves.

Revenue growth will be measured through active devices, paid users, subscriptions, sensor consumption, licensing income, and clinical deployments rather than theoretical patient eligibility. The companies that convert repeatable human-study performance into a manufacturable and regulated product will define the commercial market now emerging from a long period of scientific experimentation.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 41.2 Million
Revenue Forecast in 2032	USD 202.0 Million
Overall Growth Rate	CAGR of 25.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Technology, By Application, By End User, By Geography
By Product Type	Wearable Continuous Monitoring Devices, Handheld/Portable Spot-Reading Devices, Patch-Based Transdermal Monitoring Devices, Tabletop/Professional Monitoring Systems
By Technology	Optical Spectroscopy, Raman Spectroscopy, Mid-Infrared Photothermal Detection, Radiofrequency and Microwave Sensing, Reverse Iontophoresis/Transdermal Extraction, Other Emerging Technologies
By Application	Type 2 Diabetes Monitoring, Type 1 Diabetes Monitoring, Prediabetes and Metabolic Health Monitoring, Gestational Diabetes Monitoring, General Wellness and Nutrition Monitoring
By End User	Homecare Users, Hospitals and Diabetes Clinics, Diagnostic and Research Centers, Wellness and Weight-Management Programs
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising demand for painless and needle-free glucose monitoring; advances in optical, photothermal, and transdermal sensing technologies; growing adoption of wearable metabolic-health devices; expanding use across diabetes management, prediabetes monitoring, nutrition, and wellness programs
Customization Option	Available upon request